Roth Capital Forecasts Higher Earnings for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – Roth Capital increased their Q1 2025 earnings per share (EPS) estimates for Gain Therapeutics in a report released on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.17). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($1.13) EPS.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.07.

A number of other research analysts also recently issued reports on GANX. Scotiabank started coverage on Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Chardan Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research note on Friday, March 28th. Roth Mkm reissued a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday, March 17th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX opened at $1.89 on Wednesday. The firm has a 50 day moving average of $2.20 and a 200 day moving average of $2.07. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $50.13 million, a price-to-earnings ratio of -1.72 and a beta of 0.14. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.04.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Sprott Inc. acquired a new stake in Gain Therapeutics in the fourth quarter worth about $30,000. Benedict Financial Advisors Inc. purchased a new position in shares of Gain Therapeutics in the 4th quarter valued at approximately $35,000. Bridgeway Capital Management LLC acquired a new stake in Gain Therapeutics in the 4th quarter worth approximately $65,000. Northern Trust Corp grew its position in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Gain Therapeutics during the 4th quarter valued at approximately $198,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.